1. Written guidelines and protocols developed by a registered pharmacist in collaboration with a practitioner which authorize collaborative drug therapy management:
(a) May authorize a pharmacist to order and use the findings of laboratory tests and examinations.
(b) May provide for collaborative drug therapy management for a patient receiving care:
(1) In a licensed medical facility; or
(2) If developed to ensure continuity of care for a patient, in any setting that is affiliated with a medical facility where the patient is receiving care. A pharmacist who modifies a drug therapy of a patient receiving care in a setting that is affiliated with a medical facility shall, within 72 hours after initiating or modifying the drug therapy, provide written notice of the initiation or modification of the drug therapy to the collaborating practitioner or enter the appropriate information concerning the drug therapy in an electronic patient record system shared by the pharmacist and the collaborating practitioner.
(c) Must state the conditions under which a prescription of a practitioner relating to the drug therapy of a patient may be changed by the pharmacist without a subsequent prescription from the practitioner.
(d) Must be approved by the Board.
2. The Board may adopt regulations which:
(a) Prescribe additional requirements for written guidelines and protocols developed pursuant to this section; and
(b) Set forth the process for obtaining the approval of the Board of such written guidelines and protocols.
(Added to NRS by 2011, 3077; A 2017, 2522) — (Substituted in revision for NRS 639.2809)